0147 GMT October 16, 2019
Teplizumab, which dampens down the immune system, was found to allow the body to continue making insulin. This stopped diabetes developing for around two years, dailymail.co.uk reported.
Unlike the type 2 form of the illness, type 1 has nothing to do with lifestyle and is instead tied to genetics.
“As anyone with type 1 diabetes will tell you, and particularly for children who are most commonly affected, every day you can delay this disease is important,” said Professor Kevan Herold who led the Yale University study.
The researchers conducted their trial on 76 patients, mostly aged between eight and 18. All were seen as high risk because relatives had diabetes.
The teplizumab treatment — given by a drip every day for two weeks — worked by staving off the destruction of insulin-producing cells.
Dr. Elizabeth Robertson of Diabetes UK said the study was ‘incredibly exciting’ because it examined the root cause of an illness affecting 400,000 Britons.